Max S. Rosen, MD

Articles by Max S. Rosen, MD

Clinical Update

New Antipsychotic Formulations for Children and Adolescents: Caution Prevails

April 1, 2026

Rebecca F. Young, MD and Max S. Rosen, MD

Rebecca F. Young, MD. Chief Child and Adolescent Psychiatry Fellow, PGY-5, Washington University School of Medicine, St. Louis, MO.

Max Rosen, MD. Assistant Professor of Psychiatry (Child); Section Chief, CAP Outpatient Services; Medical Director, Child & Adolescent Psychiatry Clinic; Clerkship Director, Department of Psychiatry, Washington University School of Medicine, St. Louis, MO.

Dr. Young and Dr. Rosen have no financial relationships with companies related to this material.

Newer antipsychotics promise novel mechanisms and fewer metabolic headaches, but the pediatric data have not caught up with the enthusiasm. This update cuts through the excitement around lumateperone, xanomeline-trospium, and TAAR1 agonists, and offers a practical framework for deciding when, if ever, to venture beyond the tried-and-true SGAs.

Clinical Update

Lithium for Children and Adolescents

November 2, 2023

Max S. Rosen, MD

Max S. Rosen, MD. Assistant Professor of Psychiatry (Child); Director, Child & Adolescent Psychiatry Outpatient Services; Washington University School of Medicine, St. Louis, MO.

Dr. Rosen has no financial relationships with companies related to this material.

Lithium is FDA-approved for bipolar disorder in children and adolescents 12 years and up; however, its potential off-label utility is broad, from affective aggression to anorexia nervosa. This clinical update covers how to prescribe lithium for children and adolescents and how to talk with patients and parents about lithium.